We work with specialist royalty funds, family offices, sovereign and pension capital, and institutional allocators with mandates for pharmaceutical royalties. The proposition is simple: long-tail royalty opportunities originated for you in segments BD teams cannot internally cover, with structural analysis and comparables packaged alongside every introduction. We are not a principal and not a placement agent; the transactions are yours to underwrite and execute.
Systematic identification of royalty-eligible assets across more than 20,000 drugs and assets in development. Private companies, university tech transfer offices, research foundations, and emerging biotech with partnered assets — all the segments that sit outside sell-side bandwidth. We surface the holders, you pursue the transactions.
Long-tail positions grouped into thematic clusters — by therapeutic area, by stage, by structural feature — so that one analytical package addresses a coherent slice of the market rather than a single disconnected asset. Capital partners can engage with a theme rather than chase individual disclosures.
Every position is benchmarked against four decades of comparable transactions. Rate band, multiple discipline, structural-feature comparables, and outcome history packaged alongside every position. The buyer's underwriting starts from a structured baseline rather than a blank page.
The relationship model depends on how active you want to be in shaping the origination agenda. We have worked with each of the three structures below; the right one depends on your investment cadence, mandate parameters, and team capacity.
| Model | Best for | What you receive |
|---|---|---|
| Origination subscription | Funds with active BD teams who want a continuous flow of originated long-tail opportunities | Quarterly origination flow with structural analysis and benchmarking against the corpus, scoped to your mandate parameters. You evaluate, underwrite, and transact under your own diligence. |
| Bespoke origination | Family offices and allocators with a specific therapeutic-area or structural-feature thesis | Targeted origination against your thesis. Outputs are written analyses of opportunities matching specific criteria — therapeutic area, stage, structure — on your timetable. |
| Lead-partner research | Capital partners who want to anchor a specific theme and have origination workstreams oriented around it | Dedicated origination and research workstream on a defined theme. Coverage of the universe is yours to act on; transactions remain bilateral between you, the holder, and respective advisors. |
Specific commercial terms are negotiated case by case. We do not publish them on this site. Capital for Cures is an origination platform — research and advisory in nature. We are not a regulated investment manager, broker-dealer, or placement agent.
We share a strategy memo and pipeline overview with prospective capital partners under NDA. The memo describes our research process in operational detail, the structural features of the long-tail segment we focus on, and a coverage summary as of the most recent quarter.
Write directly to sebastian@capitalforcures.com or use the contact form.
